Our Case Studies

VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration. ​

A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.

A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.

Medical device company, Mi-Helper, Inc., needed to find participants with a specific type of migraine. This required a long run-in period and mitigation to reduce the risk of drop-off before participants reached active treatment. In addition, Mi-Helper needed to ensure participants used the at-home device properly.

A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.